The emergence of neoadjuvant therapy in advanced melanoma

被引：11

作者：

Sun, James ^{[1
]}

Kirichenko, Dennis A. ^{[2
]}

Zager, Jonathan S. ^{[1
]}

Eroglu, Zeynep ^{[1
]}

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, Dept Cutaneous Oncol, Tampa, FL 33612 USA

[2] Univ S Florida, Morsani Coll Med, Tampa, FL 33612 USA

来源：

MELANOMA MANAGEMENT | 2019年 / 6卷 / 03期

关键词：

advanced melanoma; biochemotherapy; immunotherapy; intralesional therapy; melanoma; metastatic melanoma; neoadjuvant; oncolyticvirus; targeted therapy; HIGH RESPONSE RATE; PHASE-III TRIAL; STAGE-III; METASTATIC MELANOMA; OPEN-LABEL; HIGH-RISK; BIOCHEMOTHERAPY; INTERLEUKIN-2; DACARBAZINE; COMBINATION;

D O I：

10.2217/mmt-2019-0007

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The discovery of immunotherapy and targeted therapy has introduced new and effective treatment options for advanced melanoma, providing therapeutic options where none existed before. The natural extension of these novel therapies is to identify their role in the neoadjuvant setting. Neoadjuvant therapy for advanced melanoma is still in its infancy, with a wealth of clinical trials underway. Early results are promising, allowing for management of a disease that previously had few options. We review the current literature and interim results from several ongoing investigations to understand the current state of neoadjuvant treatment options and what is to come. These studies pave the way for further advancements in melanoma therapy.

引用

页数：11

共 44 条

[21] A randomized phase III trial of biochemotherapy versus interferon-α-2b for adjuvant therapy in patients at high risk for melanoma recurrence [J].

Kim, Kevin B. ;

Legha, Sewa S. ;

Gonzalez, Rene ;

Anderson, Clay M. ;

Johnson, Marcella M. ;

Liu, Ping ;

Papadopoulos, Nicholas E. ;

Eton, Omar ;

Plager, Carl ;

Buzaid, Antonio C. ;

Prieto, Victor G. ;

Hwu, Wen-Jen ;

Frost, Angela M. ;

Alvarado, Gladys ;

Hwu, Patrick ;

Ross, Merrick I. ;

Gershenwald, Jeffrey E. ;

Lee, Jeffrey E. ;

Mansfield, Paul F. ;

Benjamin, Robert S. ;

Bedikian, Agop Y. .

MELANOMA RESEARCH, 2009, 19 (01) :42-49

[22] Vemurafenib As Neoadjuvant Treatment for Unresectable Regional Metastatic Melanoma [J].

Koers, Karlijn ;

Francken, Anne Brecht ;

Haanen, John B. A. G. ;

Woerdeman, Leonie A. E. ;

van der Hage, Jos A. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (16) :E251-E253

[23]

Kounalakis N, 2012, IMMUNOTHERAPY-UK, V4, P679, DOI [10.2217/imt.12.62, 10.2217/IMT.12.62]

[24]

Legha SS, 1996, ANN ONCOL, V7, P827

[25]

Legha SS, 1997, SEMIN ONCOL, V24, pS39

[26] Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma [J].

Legha, SS ;

Ring, S ;

Eton, O ;

Bedikian, A ;

Buzaid, AC ;

Plager, C ;

Papadopoulos, N .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (05) :1752-1759

[27] Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma [J].

Lewis, Karl D. ;

Robinson, William A. ;

McCarter, Martin ;

Pearlman, Nathan ;

O'Day, Steven J. ;

Anderson, Clay ;

Amatruda, Thomas T. ;

Zeng, Chan ;

Becker, Maude ;

Dollarhide, Susan ;

Matijevich, Karen ;

Gonzalez, Rene .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (19) :3157-3163

[28] ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties [J].

Liu, BL ;

Robinson, M ;

Han, ZQ ;

Branston, RH ;

English, C ;

Reay, P ;

McGrath, Y ;

Thomas, SK ;

Thornton, M ;

Bullock, P ;

Love, CA ;

Coffin, RS .

GENE THERAPY, 2003, 10 (04) :292-303

[29] Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease [J].

Liu, Jing ;

Blake, Stephen J. ;

Yong, Michelle C. R. ;

Harjunpaa, Heidi ;

Ngiow, Shin Foong ;

Takeda, Kazuyoshi ;

Young, Arabella ;

O'Donnell, Jake S. ;

Allen, Stacey ;

Smyth, Mark J. ;

Teng, Michele W. L. .

CANCER DISCOVERY, 2016, 6 (12) :1382-1399

[30] Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses [J].

Moschos, Stergios J. ;

Edington, Howard D. ;

Land, Stephanie R. ;

Rao, Uma N. ;

Jukic, Drazen ;

Shipe-Spotloe, Janice ;

Kirkwood, John M. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (19) :3164-3171

← 1 2 3 4 5 →